Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trial Simulation, Drug Selection To Be Focus Of US FDA's Drug Development Modeling Pilot

Executive Summary

Meeting requests from sponsors that focus on safety prediction will also be prioritized.

You may also be interested in...



Complex Innovative Designs Pilot Likely Satisfies Industry's Disclosure Worries

US FDA says sponsors generally won’t need to publicly disclose company or product if selected for pilot, but rather elements about design of their complex trial.

US FDA's Complex Trial Design Pilot Might Be Handicapped By Disclosure Requirements

FDA wants to publicize some aspects of designs accepted into pilot, which might discourage industry participation.

US FDA Offers Sponsors More Attention For Sharing Complex Innovative Trial Designs

Pilot program will select two trial designs per quarter, but sponsors want to know how much information they must disclose.

Related Content

Topics

UsernamePublicRestriction

Register

PS122904

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel